A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma

BEAT-meso: BEvacizumab and ATezolizumab in malignant pleural mesothelioma

Chemotherapy with cisplatin plus pemetrexed it the currently approved standard as first-line therapy for patients with malignant pleural mesothelioma. The best survival outcome to date has been achieved by combining standard chemotherapy with bevacizumab. However, new treatment strategies are needed in order to further improve outcome. Immunotherapy has achieved promising results in a subset of patients with PD-L1-positive tumours in the second-line setting

The aim of the BEAT-meso trial is to address whether the addition of the anti-PD-L1 antibody atezolizumab given in combination with standard chemotherapy plus bevacizumab improves the outcome in advanced treatment-naïve malignant pleural mesothelioma patients.

Trial Scheme

ETOP 13 18 BEAT meso Trial Scheme

 

Primary endpoint: Progression free survival & Overall survival
Secondary endpoints:

Response rate

Disease control rate

Time to treatment failure

Duration of response

Safety and tolerability

Patient reported outcome

Quality of life

Target Sample Size: 320 Randomised Patients 
Protocol Release: TBD

Trial Organisation

Trial Chair: Enriqueta Felip
Trial Co-Chair: Sanjay Popat
Sponsor: ETOP
Coordinating Groups: ETOP
Participating Groups: SAKK and SLCG
Participating Countries:
Belgium, France, Italy, Portugal, Slovenia, Spain, Switzerland and United Kingdom
Registrations:

EudraCT number: 2018-002180-25

ClinicalTrials.gov:

  

Contact:

Florence Berger (Trial Manager)

Tel: +41 31 511 94 48

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

European Thoracic Oncology Platform

c/o IBCSG

Effingerstrasse 40

3008 Bern, Switzerland

Tel: +41 31 511 94 00